Search Prime Grants

R35GM139566

Project Grant

Overview

Grant Description
Volatile Anesthetics and Metabolism - Project Summary

A true enigma of modern medicine has persisted for over 150 years; the mechanism(s) by which volatile anesthetics (VAs) produce reversible loss of consciousness remains an unsolved mystery. Using genetic approaches, we demonstrated that mitochondrial complex I, an entry point of the mitochondrial electron transport chain, specifically controls the sensitivity of multiple species, including worms and humans, to VAs. These broad phylogenetic effects indicate that an ancient mechanism is at hand, linking mitochondrial function to synaptic silencing in the presence of VAs.

We began mechanistic studies in mice by exploiting NDUFS4(KO), a mouse defective in complex I function and extremely hypersensitive to VAs. Testing cell-specific NDUFS4(KO) mice, we found that VA sensitivity was fully controlled by glutamatergic KO, with no effect of loss of NDUFS4 from GABAergic or cholinergic neurons. Surprisingly, an astrocytic-specific KO of NDUFS4 was defective only in arousal from VAs. Preliminary data indicate that neurons in the locus coeruleus mediate this effect. This novel role of astrocytes offers a new approach to investigate crucial arousal pathways.

In addition, we are exploring the mechanisms underlying anesthetic-induced neurotoxicity (AIN). From our work in nematodes, we have identified new candidate molecules that can be tested as AIN therapies in mice. We showed that inhibition of the unfolded protein response in the endoplasmic reticulum, or inhibition of mTOR, a cellular metabolic switch, alleviated AIN in worms. We are exploring the roles of these pathways in AIN, and relating them to exciting new data which indicate that VAs themselves produce metabolic changes specific to neonatal mice. Many questions remain unanswered.

1. How do complex I defects control VA sensitivity? We showed that excitatory neurotransmission in NDUFS4(KO) was hypersensitive to isoflurane inhibition compared to WT. Our recent data suggest that isoflurane inhibits synaptic endocytosis in both WT and KO animals and that this inhibition results from a decrease in ATP production. Our aims are to characterize the mechanism underlying inhibition of neurotransmitter endocytosis by VAs.

2. What pathways transduce AIN in neonatal mice; how can those pathways be inhibited? We are extending C. elegans studies to test exciting new small molecule candidates that may alleviate AIN in mice. We are also exploring ER-stress and mTOR activity as potential signaling pathways mediating AIN in mice.

3. How does mitochondrial function in astrocytes control arousal from the anesthetized state? We are studying astrocyte signaling to determine how astrocytes affect synaptic function during and following VA exposure. Astrocyte/neural pathways necessary for emergence from the anesthetized state will be investigated. Mitochondrial function is linked to behavior in VAs in worms, mice, and man. Our proposed studies are aimed to identify the basic, molecular mechanisms of action of VAs.
Funding Goals
THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) SUPPORTS BASIC RESEARCH THAT INCREASES OUR UNDERSTANDING OF BIOLOGICAL PROCESSES AND LAYS THE FOUNDATION FOR ADVANCES IN DISEASE DIAGNOSIS, TREATMENT, AND PREVENTION. NIGMS ALSO SUPPORTS RESEARCH IN SPECIFIC CLINICAL AREAS THAT AFFECT MULTIPLE ORGAN SYSTEMS: ANESTHESIOLOGY AND PERI-OPERATIVE PAIN, CLINICAL PHARMACOLOGY ?COMMON TO MULTIPLE DRUGS AND TREATMENTS, AND INJURY, CRITICAL ILLNESS, SEPSIS, AND WOUND HEALING.? NIGMS-FUNDED SCIENTISTS INVESTIGATE HOW LIVING SYSTEMS WORK AT A RANGE OF LEVELSFROM MOLECULES AND CELLS TO TISSUES AND ORGANSIN RESEARCH ORGANISMS, HUMANS, AND POPULATIONS. ADDITIONALLY, TO ENSURE THE VITALITY AND CONTINUED PRODUCTIVITY OF THE RESEARCH ENTERPRISE, NIGMS PROVIDES LEADERSHIP IN SUPPORTING THE TRAINING OF THE NEXT GENERATION OF SCIENTISTS, ENHANCING THE DIVERSITY OF THE SCIENTIFIC WORKFORCE, AND DEVELOPING RESEARCH CAPACITY THROUGHOUT THE COUNTRY.
Place of Performance
Seattle, Washington 981011304 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the total obligations have increased 415% from $819,975 to $4,223,231.
Seattle Children's Hospital was awarded Volatile Anesthetics & Metabolism: Mechanisms & Therapies Project Grant R35GM139566 worth $4,223,231 from the National Institute of General Medical Sciences in March 2021 with work to be completed primarily in Seattle Washington United States. The grant has a duration of 5 years and was awarded through assistance program 93.859 Biomedical Research and Research Training. The Project Grant was awarded through grant opportunity Maximizing Investigators' Research Award (R35 - Clinical Trial Optional).

Status
(Ongoing)

Last Modified 9/5/25

Period of Performance
3/1/21
Start Date
2/28/26
End Date
92.0% Complete

Funding Split
$4.2M
Federal Obligation
$0.0
Non-Federal Obligation
$4.2M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to R35GM139566

Transaction History

Modifications to R35GM139566

Additional Detail

Award ID FAIN
R35GM139566
SAI Number
R35GM139566-1058681866
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NS00 NIH National Institute of General Medical Sciences
Funding Office
75NS00 NIH National Institute of General Medical Sciences
Awardee UEI
SZ32VTCXM799
Awardee CAGE
0Y4X2
Performance District
WA-07
Senators
Maria Cantwell
Patty Murray

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Institute of General Medical Sciences, National Institutes of Health, Health and Human Services (075-0851) Health research and training Grants, subsidies, and contributions (41.0) $1,639,950 100%
Modified: 9/5/25